SG11201403106SA - Anti-phf-tau antibodies and their uses - Google Patents
Anti-phf-tau antibodies and their usesInfo
- Publication number
- SG11201403106SA SG11201403106SA SG11201403106SA SG11201403106SA SG11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA SG 11201403106S A SG11201403106S A SG 11201403106SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pennsylvania
- rule
- king
- johnson
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577817P | 2011-12-20 | 2011-12-20 | |
| PCT/US2012/070486 WO2013096380A2 (fr) | 2011-12-20 | 2012-12-19 | Anticorps anti-phf-tau et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201403106SA true SG11201403106SA (en) | 2014-12-30 |
Family
ID=48669693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403106SA SG11201403106SA (en) | 2011-12-20 | 2012-12-19 | Anti-phf-tau antibodies and their uses |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US9371376B2 (fr) |
| EP (2) | EP2794654B1 (fr) |
| JP (4) | JP6306513B2 (fr) |
| KR (1) | KR101991681B1 (fr) |
| CN (2) | CN107226863B (fr) |
| AU (2) | AU2012359039B2 (fr) |
| BR (1) | BR112014015323B1 (fr) |
| CA (2) | CA3234629A1 (fr) |
| CO (1) | CO6980627A2 (fr) |
| CY (1) | CY1121862T1 (fr) |
| DK (1) | DK2794654T3 (fr) |
| EA (1) | EA027975B1 (fr) |
| EC (1) | ECSP14005975A (fr) |
| ES (1) | ES2738007T3 (fr) |
| GT (1) | GT201400127A (fr) |
| HK (2) | HK1203520A1 (fr) |
| HR (1) | HRP20191342T1 (fr) |
| HU (1) | HUE045656T2 (fr) |
| IL (3) | IL233051B (fr) |
| LT (1) | LT2794654T (fr) |
| MX (1) | MX350311B (fr) |
| MY (2) | MY178142A (fr) |
| NI (1) | NI201400061A (fr) |
| NZ (1) | NZ626269A (fr) |
| PH (1) | PH12014501427A1 (fr) |
| PL (1) | PL2794654T3 (fr) |
| PT (1) | PT2794654T (fr) |
| RS (1) | RS59024B1 (fr) |
| SG (1) | SG11201403106SA (fr) |
| SI (1) | SI2794654T1 (fr) |
| TR (1) | TR201910720T4 (fr) |
| UA (1) | UA114902C2 (fr) |
| WO (1) | WO2013096380A2 (fr) |
| ZA (1) | ZA201405317B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2794654T1 (sl) * | 2011-12-20 | 2019-08-30 | Janssen Biotech, Inc. | Protitelesa proti PHF-tau njihove uporabe |
| WO2014008404A1 (fr) | 2012-07-03 | 2014-01-09 | Washington University | Anticorps dirigés contre tau |
| US9567395B2 (en) | 2012-08-16 | 2017-02-14 | Ipierian, Inc. | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| US10400034B2 (en) * | 2014-06-26 | 2019-09-03 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| WO2016112078A2 (fr) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anticorps tau/anti-phf et leurs utilisations |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| AU2016270858B2 (en) | 2015-06-05 | 2022-04-28 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| UA124616C2 (uk) * | 2015-07-06 | 2021-10-20 | Юсб Біофарма Срл | Зв'язуюче тау-білок антитіло |
| CA2991264C (fr) * | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CA3032692A1 (fr) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Polytherapie a base d'anticorps pour le traitement de maladies neurodegeneratives |
| TW202328181A (zh) * | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
| KR20240035636A (ko) | 2016-12-07 | 2024-03-15 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
| CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| KR102225178B1 (ko) | 2017-10-16 | 2021-03-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-타우 항체 및 그의 용도 |
| CA3093200A1 (fr) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anticorps anti-phf-tau et leurs utilisations |
| EP3762414A4 (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica NV | Dosages pour détecter la neurodégénérescence |
| BR112020018868A2 (pt) * | 2018-03-28 | 2021-01-26 | Axon Neuroscience Se | métodos baseados em anticorpo para detectar e tratar doença de alzheimer |
| EP3829634A1 (fr) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Polythérapie |
| BR112022020753A2 (pt) | 2020-04-15 | 2022-12-20 | Voyager Therapeutics Inc | Compostos de ligação a tau |
| US11702467B2 (en) | 2020-06-25 | 2023-07-18 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| EP4263599A1 (fr) | 2020-12-16 | 2023-10-25 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
| EP4314059A1 (fr) | 2021-03-26 | 2024-02-07 | Janssen Biotech, Inc. | Anticorps humanisés dirigés contre le filament hélicoïdal tau apparié et leurs utilisations |
| AU2022242135A1 (en) * | 2021-03-26 | 2023-11-09 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| WO2023250388A1 (fr) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Composés se liant à la protéine tau |
| WO2024059739A1 (fr) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993008302A1 (fr) * | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Anticorps monoclonaux diriges contre la proteine tau associee aux microtubules |
| CA2178212C (fr) * | 1993-12-21 | 2011-06-14 | Marc Vandermeeren | Anticorps monoclonaux specifiques de phf-tau, hybridomes les secretant, reconnaissance des antigenes par ces anticorps et leurs applications |
| WO1996004309A1 (fr) | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Anticorps monoclonaux specifiques d'un epitope d'une sous-classe ou forme particuliere de tau phosphorylee, hybridomes les secretant, reconnaissance par les antigenes de ces anticorps et leurs applications |
| EP2298809A3 (fr) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Anticorps super humanisés |
| WO2005056759A2 (fr) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| CN101626783A (zh) * | 2006-08-04 | 2010-01-13 | 诺华有限公司 | Ephb3-特异性抗体和其应用 |
| JP2010235447A (ja) * | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| EP2347038A4 (fr) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | Procédés d humanisation et de maturation d affinité d anticorps |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| EP4218794A3 (fr) | 2009-06-10 | 2023-09-13 | New York University | Ciblage immunologique de protéines tau pathologiques |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8912355B2 (en) * | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| DK2488867T3 (da) | 2009-10-14 | 2020-11-09 | Janssen Biotech Inc | Fremgangsmåder til affinitetsmodning af antistoffer |
| CA2812865C (fr) * | 2010-10-07 | 2021-01-26 | Ac Immune S.A. | Anticorps phosphospecifiques reconnaissant la proteine tau |
| WO2012049570A1 (fr) | 2010-10-11 | 2012-04-19 | Panima Pharmaceuticals Ag | Anticorps anti-tau humain |
| SI2794654T1 (sl) * | 2011-12-20 | 2019-08-30 | Janssen Biotech, Inc. | Protitelesa proti PHF-tau njihove uporabe |
-
2012
- 2012-12-19 SI SI201231610T patent/SI2794654T1/sl unknown
- 2012-12-19 CN CN201710472573.8A patent/CN107226863B/zh active Active
- 2012-12-19 WO PCT/US2012/070486 patent/WO2013096380A2/fr active Application Filing
- 2012-12-19 US US14/363,888 patent/US9371376B2/en active Active
- 2012-12-19 UA UAA201408042A patent/UA114902C2/uk unknown
- 2012-12-19 NZ NZ626269A patent/NZ626269A/en unknown
- 2012-12-19 MY MYPI2014701643A patent/MY178142A/en unknown
- 2012-12-19 CA CA3234629A patent/CA3234629A1/fr active Pending
- 2012-12-19 SG SG11201403106SA patent/SG11201403106SA/en unknown
- 2012-12-19 KR KR1020147019911A patent/KR101991681B1/ko active IP Right Grant
- 2012-12-19 JP JP2014548811A patent/JP6306513B2/ja active Active
- 2012-12-19 EP EP12859920.6A patent/EP2794654B1/fr active Active
- 2012-12-19 CA CA2859665A patent/CA2859665C/fr active Active
- 2012-12-19 RS RS20190932A patent/RS59024B1/sr unknown
- 2012-12-19 MX MX2014007476A patent/MX350311B/es active IP Right Grant
- 2012-12-19 LT LT12859920T patent/LT2794654T/lt unknown
- 2012-12-19 PT PT12859920T patent/PT2794654T/pt unknown
- 2012-12-19 AU AU2012359039A patent/AU2012359039B2/en active Active
- 2012-12-19 EP EP19173615.6A patent/EP3578567A1/fr active Pending
- 2012-12-19 EA EA201491224A patent/EA027975B1/ru not_active IP Right Cessation
- 2012-12-19 PL PL12859920T patent/PL2794654T3/pl unknown
- 2012-12-19 HU HUE12859920A patent/HUE045656T2/hu unknown
- 2012-12-19 CN CN201280062971.8A patent/CN104024274B/zh active Active
- 2012-12-19 ES ES12859920T patent/ES2738007T3/es active Active
- 2012-12-19 TR TR2019/10720T patent/TR201910720T4/tr unknown
- 2012-12-19 BR BR112014015323-0A patent/BR112014015323B1/pt active IP Right Grant
- 2012-12-19 MY MYPI2017000364A patent/MY186066A/en unknown
- 2012-12-19 DK DK12859920.6T patent/DK2794654T3/da active
-
2014
- 2014-06-10 IL IL233051A patent/IL233051B/en active IP Right Grant
- 2014-06-19 NI NI201400061A patent/NI201400061A/es unknown
- 2014-06-20 EC ECIEPI20145975A patent/ECSP14005975A/es unknown
- 2014-06-20 PH PH12014501427A patent/PH12014501427A1/en unknown
- 2014-06-20 CO CO14134449A patent/CO6980627A2/es unknown
- 2014-06-20 GT GT201400127A patent/GT201400127A/es unknown
- 2014-07-18 ZA ZA2014/05317A patent/ZA201405317B/en unknown
-
2015
- 2015-04-24 HK HK15103967.6A patent/HK1203520A1/xx unknown
-
2016
- 2016-04-26 US US15/138,635 patent/US9745371B2/en active Active
-
2017
- 2017-07-11 US US15/646,865 patent/US10000559B2/en active Active
- 2017-11-20 AU AU2017264975A patent/AU2017264975B2/en active Active
- 2017-12-21 JP JP2017245019A patent/JP6695317B2/ja active Active
-
2018
- 2018-03-07 HK HK18103213.5A patent/HK1244490A1/zh unknown
- 2018-05-21 US US15/984,772 patent/US10196440B2/en active Active
- 2018-11-14 IL IL263021A patent/IL263021B/en active IP Right Grant
-
2019
- 2019-06-10 JP JP2019108147A patent/JP6987809B2/ja active Active
- 2019-07-25 HR HRP20191342 patent/HRP20191342T1/hr unknown
- 2019-08-06 CY CY20191100834T patent/CY1121862T1/el unknown
-
2020
- 2020-02-10 JP JP2020020482A patent/JP6987904B2/ja active Active
-
2021
- 2021-03-03 IL IL281250A patent/IL281250A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201408261UA (en) | Syringe | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201406963RA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
| SG11201407505XA (en) | Aptamer-based multiplexed assays | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof |